Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.
Financial Results:
Windlas Biotech Ltd reported Revenues for Q1FY24 of ₹145.00 Crores up from ₹120.00 Crore year on year, a rise of 20.83%.
Total Expenses for Q1FY24 of ₹131.00 Crores up from ₹109.00 Crores year on year, a rise of 20.18%.
Consolidated Net Profit of ₹12.00 Crores up 20.0% from ₹10.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹5.67, up 26.00% from ₹4.50 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.